MoonLake Immunotherapeutics Class A (MLTX)

MoonLake Immunotherapeutics' stock price has experienced significant volatility in the past six months. A major decline occurred after disappointing Week 16 results from Phase 3 VELA trials for sonelokimab, causing a nearly 90% stock plummet and subsequent analyst downgrades. A securities fraud class action lawsuit was filed against the company, alleging materially false and misleading statements about sonelokimab's clinical prospects. Despite the drop, the stock saw a 4.5% gain on November 5, 2025, following an earnings announcement, and has drifted 22.8% higher since then. On November 5, 2025, MoonLake also announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares. As of November 26, 2025, the stock price was $13.80.

There is no specific information available regarding demand seasonality for MoonLake Immunotherapeutics' products and services, as the company is in the clinical stage and its revenue is currently reported as $0.00. Traditional demand seasonality for commercialized products does not apply at this stage.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, operating within the Health Technology sector, specifically the Pharmaceuticals: Major industry. Their primary product candidate is Sonelokimab (SLK), a novel tri-specific Nanobody designed to inhibit IL-17A and IL-17F, which play a significant role in inflammatory diseases. The company aims to provide next-level therapies to address unmet needs in conditions like hidradenitis suppurativa, psoriatic arthritis, and psoriasis.

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and was founded in 2021. In July 2021, the company also registered a UK subsidiary.

MoonLake Immunotherapeutics' brand reputation has been significantly impacted, particularly in late September 2025, due to disappointing Phase 3 trial results for sonelokimab, leading to a stock crash and a securities fraud class action lawsuit. Analysts described the trial outcome as "disastrous," further damaging the company's standing and casting a shadow over MoonLake's reputation.

MoonLake Immunotherapeutics has a mixed ownership structure, with institutional investors holding approximately 56.04% to 56.59% of the stock, insiders owning about 40.33%, and public companies and individual investors holding a smaller percentage. As of September 30, 2025, there were 267 institutional owners and shareholders. BVF Partners L.P. is noted as the company's largest shareholder, with 59% of shares outstanding as of July 26, 2022.